| Literature DB >> 35463090 |
Muhammad Ayaz1, Abdul Sadiq1, Osama F Mosa2,3, Tariq Abdalla Zafar2, Alashary Adam Eisa Hamdoon2,4, Modawy Elnour Modawy Elkhalifa2,4, Mohammed Ahmed Elawad2,4, Alshebli Ahmed2,4, Farhat Ullah1, Mehreen Ghufran5, Atul Kabra6.
Abstract
Introduction: Natural products are among the most useful sources for the discovery of new drugs against various diseases. Keeping in view the ethnobotanical relevance ethnopharmacological significance of Polygonaceae family in diabetes, the current study was designed to isolate pure compounds from Persicaria hydropiper L. leaves and evaluate their in vitro and in silico antidiabetic potentials.Entities:
Year: 2022 PMID: 35463090 PMCID: PMC9023165 DOI: 10.1155/2022/6705810
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.650
Figure 1Structures of isolated bioactive compounds from P. hydropiper.
Figure 2Results of the DPPH antiradicals assay exhibited by isolated compounds. (a) Ph-1, (b) Ph-2, (c) Ph-3, (d) Ph-4, (e) Ph-5, (f) Ph-6, and (g) positive control/ascorbic acid.
Figure 3Results of the ABTS antiradicals assay exhibited by isolated compounds. (a) Ph-1, (b) Ph-2, (c) Ph-3, (d) Ph-4, (e) Ph-5, (f) Ph-6, and (g) positive control/ascorbic acid.
Results of α-glucosidase/α-amylase inhibitory assays.
| Samples |
|
| ||||
|---|---|---|---|---|---|---|
| Conc. | % enzyme inhibition | IC50 | Conc. | % enzyme inhibition | IC50 | |
| Ph-1 | 1000 | 81.84 ± 0.32ns | 85 | 1000 | 75.83 ± 1.07 ns | 69.48 |
| Ph-2 | 1000 | 78.79 ± 0.63 ns | 170 | 1000 | 71.62 ± 0.74 ns | 252.01 |
| Ph-3 | 1000 | 55. 44 ± 0.09 | 474.83 | 1000 | 57.33 ± 0.88 | 332.19 |
| Ph-4 | 1000 | 64.36 ± 0.61 | 455.94 | 1000 | 72.51 ± 0.62ns | 333.25 |
| Ph-5 | 1000 | 67.37 ± 0.68 | 228 | 1000 | 64.23 ± 0.44 | 370 |
| Ph-6 | 1000 | 58. 91 ± 1.54 | 337.94 | 1000 | 61.33 ± 0.88 | 271.24 |
| P. Control | 1000 | 89.42 ± 0.55 | 40 | 1000 | 85.72 ± 0.66 | 45 |
For the statistical difference among the test samples and positive control, one-way ANOVA followed by multiple comparison Dunnett's test was applied to the data. , p < 0.001, p < 0.01, p < 0.01 and ns: values not significantly different when compared with standard drug inhibitions (Acarbose) at the same tested concentrations.
Docking scores and report of predicted interactions of docked conformations of compounds against α-glucosidase.
| S. no. | Ligand | Receptor | Interaction | Distance | E (kcal/mol) | Docking score | |||
|---|---|---|---|---|---|---|---|---|---|
| 1 | C | 16 | OE2 | GLU | 304 | H-donor | 3.38 | −0.1 | −12.4286 |
| C | 40 | O | ASP | 349 | H-donor | 2.93 | −0.1 | ||
| C | 42 | OD2 | ASP | 349 | H-donor | 3.88 | −0.1 | ||
| C | 45 | OE1 | GLU | 276 | H-donor | 2.79 | −0.1 | ||
| C | 45 | OE2 | GLU | 276 | H-donor | 3.54 | −0.1 | ||
| C | 52 | OD2 | ASP | 349 | H-donor | 3.9 | −0.1 | ||
| C | 56 | OD2 | ASP | 68 | H-donor | 3.17 | −0.1 | ||
| O | 79 | ND2 | ASN | 241 | H-acceptor | 2.89 | −3 | ||
| C | 6 | 5-ring | HIS | 279 | H-pi | 4.28 | −0.1 | ||
| C | 11 | 6-ring | PHE | 157 | H-pi | 3.74 | −0.9 | ||
| C | 54 | 6-ring | PHE | 177 | H-pi | 3.75 | −0.3 | ||
| 2 | C | 57 | O | SER | 308 | H-donor | 4.13 | −0.1 | −11.9020 |
| C | 57 | O | PRO | 309 | H-donor | 3.53 | −0.1 | ||
| C | 57 | O | PHE | 310 | H-donor | 3.43 | −0.1 | ||
| O | 69 | O | ASP | 349 | H-donor | 2.85 | −1.5 | ||
| O | 69 | CG | GLN | 350 | H-acceptor | 3.33 | −0.1 | ||
| C | 44 | 6-ring | PHE | 157 | H-pi | 3.15 | −0.1 | ||
| C | 48 | 5-ring | HIS | 279 | H-pi | 4.54 | −0.1 | ||
| C | 61 | 5-ring | HIS | 279 | H-pi | 4.52 | −0.2 | ||
| 3 | C | 3 | O | ASP | 349 | H-donor | 3.03 | −1 | −7.4657 |
| O | 10 | CG2 | VAL | 303 | H-acceptor | 3.87 | −0.1 | ||
| O | 17 | CE1 | TYR | 313 | H-acceptor | 2.93 | −0.4 | ||
| 4 | C | 13 | OE1 | GLN | 350 | H-donor | 3.29 | −0.1 | −6.8211 |
| C | 13 | 6-ring | PHE | 300 | H-pi | 4.73 | −0.3 | ||
| −6 | ring | CD | ARG | 312 | pi-H | 4.2 | −0.1 | ||
| 5 | C | 17 | OD2 | ASP | 68 | H-donor | 3.8 | −0.1 | −10.6611 |
| C | 25 | O | ASP | 349 | H-donor | 3.84 | −0.1 | ||
| C | 25 | OE1 | GLN | 350 | H-donor | 3.66 | −0.1 | ||
| O | 30 | NE2 | HIS | 348 | H-acceptor | 2.71 | −2 | ||
| C | 13 | 5-ring | HIS | 348 | H-pi | 4.48 | −0.4 | ||
| −6 | ring | CD | ARG | 439 | pi-H | 4.15 | −0.1 | ||
| 6 | C | 3 | O | SER | 156 | H-donor | 3.63 | −0.1 | −10.7079 |
| C | 6 | OD2 | ASP | 408 | H-donor | 3.58 | −0.1 | ||
| C | 27 | OE1 | GLN | 350 | H-donor | 3.65 | −0.2 | ||
| C | 6 | 6-ring | PHE | 311 | H-pi | 3.67 | −0.1 | ||
| −6-ring | CB | ARG | 312 | pi-H | 4.91 | −0.2 | |||
| Acarbose | C | 23 | OD1 | ASP | 214 | H-donor | 2.91 | −0.8 | −5.3602 |
| O | 33 | OE1 | GLN | 181 | H-donor | 3.25 | −1 | ||
| O | 34 | OD2 | ASP | 408 | H-donor | 3.57 | −0.5 | ||
| O | 37 | OD2 | ASP | 214 | H-donor | 2.86 | −2.5 | ||
| O | 16 | ND2 | ASN | 347 | H-acceptor | 2.7 | −3 | ||
| O | 25 | NE | ARG | 312 | H-acceptor | 2.56 | −3.5 | ||
| O | 37 | NE2 | HIS | 111 | H-acceptor | 2.49 | −2.7 | ||
| N | 32 | 6-ring | PHE | 177 | Cation-pi | 4.04 | −1 | ||
Figure 4Results of the docking studies of Ph-1 (a) and Ph-2 (b) against α-glucosidase enzyme.
Figure 5Docking conformation of (a) compound Ph-1 and (b) compound Ph-2 in the active site of α-amylase.
Docking scores and report of predicted interactions of docked conformations of compounds against α-amylase.
| S. no. | Ligand | Receptor | Interaction | Distance | E (kcal/mol) | Docking score | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | C | 6 | OD1 | ASP | 197 | (A) | H-donor | 3.38 | −0.1 | −6.9473 |
| C | 16 | OD1 | ASP | 300 | (A) | H-donor | 3.54 | −0.1 | ||
| C | 16 | OD2 | ASP | 300 | (A) | H-donor | 3.42 | −0.1 | ||
| C | 32 | OD2 | ASP | 300 | (A) | H-donor | 3.64 | −0.1 | ||
| C | 59 | OE2 | GLU | 240 | (A) | H-donor | 3.59 | −0.1 | ||
| O | 79 | OD2 | ASP | 197 | (A) | H-donor | 2.56 | −1.9 | ||
| O | 79 | CB | TYR | 62 | (A) | H-acceptor | 3.36 | −0.3 | ||
| O | 79 | NE2 | HIS | 101 | (A) | H-acceptor | 2.98 | −1 | ||
| 2 | C | 6 | OD2 | ASP | 197 | (A) | H-donor | 3.93 | −0.1 | −6.6032 |
| C | 11 | OD1 | ASP | 300 | (A) | H-donor | 3.44 | −0.1 | ||
| O | 69 | NH2 | ARG | 195 | (A) | H-acceptor | 3.23 | −0.3 | ||
| O | 69 | NE2 | HIS | 299 | (A) | H-acceptor | 3.45 | −0.2 | ||
| 3 | O | 10 | CZ2 | TRP | 58 | (A) | H-acceptor | 3.38 | −0.1 | −4.2675 |
| 4 | C | 5 | OD2 | ASP | 197 | (A) | H-donor | 3.33 | −0.1 | −4.3894 |
| O | 19 | NH2 | ARG | 195 | (A) | H-acceptor | 2.88 | −1.7 | ||
| O | 19 | NE2 | HIS | 299 | (A) | H-acceptor | 2.93 | −4.4 | ||
| 6-ring | CB | ALA | 198 | (A) | pi-H | 3.73 | −0.4 | |||
| 5 | C | 13 | OD1 | ASP | 300 | (A) | H-donor | 2.94 | −0.2 | 58.5320 |
| 6 | C | 6 | O | THR | 163 | (A) | H-donor | 3.71 | −0.1 | −4.0766 |
| O | 25 | CD2 | LEU | 162 | (A) | H-acceptor | 3.84 | −0.1 | ||
| 6-ring | CD1 | LEU | 162 | (A) | pi-H | 4.31 | −0.2 | |||
| P.C | O3F | 7 | OD2 | ASP | 300 | (A) | H-donor | 2.59 | −2.5 | −4.0028 |
| O29 | 55 | O | TYR | 62 | (A) | H-donor | 2.65 | −3.2 | ||
| O2A | 70 | OE2 | GLU | 240 | (A) | H-donor | 2.72 | −3.3 | ||
| O3A | 72 | OE1 | GLU | 240 | (A) | H-donor | 2.75 | −3.4 | ||
| O9F | 16 | NE2 | HIS | 305 | (A) | H-acceptor | 2.92 | −4.1 | ||
P.C: positive control/standard.